PMID- 15269154
OWN - NLM
STAT- MEDLINE
DCOM- 20050119
LR  - 20141120
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 10
IP  - 14
DP  - 2004 Jul 15
TI  - Interlaboratory comparison of HER-2 oncogene amplification as detected by 
      chromogenic and fluorescence in situ hybridization.
PG  - 4793-8
AB  - PURPOSE: Chromogenic in situ hybridization (CISH) is a new modification of the 
      fluorescence in situ hybridization (FISH) technique for detection of oncogene 
      amplification in archival tumor samples. In CISH, the oncogene probe is detected 
      using a peroxidase reaction, allowing use of transmitted light microscopy. We 
      compared detection of HER-2/neu amplification by CISH with a Food and Drug 
      Administration-approved two-color FISH test in an interlaboratory setting. 
      EXPERIMENTAL DESIGN: Formalin-fixed paraffin-embedded tumor samples from 197 
      breast cancers were analyzed for HER-2 amplification by CISH. Two-color FISH 
      (PathVysion) CISH of 17 centromere was done if the observer considered it 
      necessary to ascertain amplification status in tumors with borderline HER-2 CISH 
      copy numbers. RESULTS: Paired CISH/FISH results were available from 192 (97%) of 
      197 cases, no clear difference in success rates of either method was observed. 
      Centromere 17 CISH was considered necessary in seven tumors. CISH and two-color 
      FISH results were concordant in 180 cases (93.8%). There were 92 and 88 tumors 
      found HER-2 amplified and nonamplified, respectively, by both methods. Eight 
      tumors were amplified by CISH but not by FISH, and four tumors exhibited the 
      opposite condition (kappa coefficient 0.875). In 7 of 12 cases differences 
      between the two methods could have related to a lack of CISH chromosome 17 
      information. The remaining cases were explained by difficult histology (ductal 
      carcinoma in situ, poor representativity, dense lymphocytic infiltration, or 
      intratumoral heterogeneity). CONCLUSIONS: These results indicate that CISH could 
      provide an accurate and practical alternative to FISH for clinical diagnosis of 
      HER-2/neu oncogene amplification in archival formalin-fixed breast cancer 
      samples.
FAU - Isola, Jorma
AU  - Isola J
AD  - Laboratory of Cancer Genetics, Institute of Medical Technology, University and 
      University Hospital of Tampere, Tampere, Finland.
FAU - Tanner, Minna
AU  - Tanner M
FAU - Forsyth, Amanda
AU  - Forsyth A
FAU - Cooke, Timothy G
AU  - Cooke TG
FAU - Watters, Amanda D
AU  - Watters AD
FAU - Bartlett, John M S
AU  - Bartlett JM
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Breast Neoplasms/genetics/pathology
MH  - Chromosome Painting/*methods
MH  - Clinical Laboratory Techniques/standards
MH  - Female
MH  - Gene Amplification
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Receptor, ErbB-2/*genetics
MH  - Reproducibility of Results
EDAT- 2004/07/23 05:00
MHDA- 2005/01/20 09:00
CRDT- 2004/07/23 05:00
PHST- 2004/07/23 05:00 [pubmed]
PHST- 2005/01/20 09:00 [medline]
PHST- 2004/07/23 05:00 [entrez]
AID - 10/14/4793 [pii]
AID - 10.1158/1078-0432.CCR-0428-03 [doi]
PST - ppublish
SO  - Clin Cancer Res. 2004 Jul 15;10(14):4793-8. doi: 10.1158/1078-0432.CCR-0428-03.